Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease Patients

Sofia A. W. van Moorsel(Ziekenhuis Bernhoven), Dennis R. Wong(Zuyderland Medisch Centrum), Marieke Pierik(Maastricht University Medical Centre), Paul Bus(Laurentius Ziekenhuis), Rob H. Creemers(Zuyderland Medisch Centrum), Debbie S. Deben, Melek Simsek(Vrije Universiteit Amsterdam), Nanne K.H. de Boer, Björn Winkens(Centraal Bureau voor de Statistiek), Adriaan A. van Bodegraven(Maastricht University Medical Centre)
Therapeutic Drug Monitoring
September 7, 2022
10.1097/ftd.0000000000001031
Cited by 6

Related Papers

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
|The Lancet|2022|295
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
|Journal of Crohn s and Colitis|2019|183
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
|Alimentary Pharmacology & Therapeutics|2020|129
Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies
|Inflammatory Bowel Diseases|2018|103